A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Clinical trial NCT00845910 · TERMINATED
Trial details
- NCT number
- NCT00845910
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-05-01
- Primary completion
- 2011-05-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.